What is the regulatory status of Ipamorelin?

Ipamorelin regulatory status: Unapproved in the United States; WADA status banned (s2); research level phase ii in gh deficiency; off-label use widespread. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For scheduling and cycle use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Is Ipamorelin safe during pregnancy or breastfeeding?

Ipamorelin, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Should I cycle Ipamorelin?

Standard cycle for Ipamorelin is 8–12 weeks of 1-3x daily subq 200-300 mcg dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to Ipamorelin's ~2 hr half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

What are the safety considerations for Ipamorelin?

Cleanest side-effect profile among GHRPs. Mild flushing possible. Site reactions occasional. For scheduling and cycle use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Ipamorelin's ~2 hr pharmacokinetic profile and subq administration route influence the side-effect profile in predictable ways.

Home/ Compounds/ Ipamorelin

Ipamorelin

Protocol

Protocol design for Ipamorelin starts with pharmacokinetics and ends with calendar planning. The compound's ~2 hr half-life via subq administration places it in the daily-dosing bucket; cycle length is 8-12 weeks with a 4-week off-period; stack integration follows route compatibility and receptor non-overlap principles.

Protocol / Scheduling / Cycling Applications

Off-TimeWeekly TimingDaily TimingMaintenance PhasePeriodised Cycles

Key Takeaways

Scheduling lens: Ipamorelin's ~2 hr half-life via subq places it in the daily-dosing bucket.
Mechanism: Highly selective GHSR1a agonist.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, CJC-1295 without DAC (Mod GRF 1-29).

Protocol / Scheduling / Cycling Mechanism

Highly selective GHSR1a agonist. Triggers pulsatile GH release from somatotrophs without engaging the cortisol or prolactin axis at therapeutic doses. Synergistic with GHRH analogues (CJC-1295) because the two pathways converge on the same pituitary cell. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for Ipamorelin.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Ipamorelin protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Ipamorelin schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Daily and weekly timing

Ipamorelin with a ~2 hr half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1-3x daily SubQ, with consistency mattering more than the absolute clock time of any single dose.

Cycle length and off-cycle planning

Standard Ipamorelin cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Protocol / Scheduling / Cycling Applications

Stack Scheduling

For stack scheduling scheduling, Ipamorelin is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Off-Time

Schedule design for Ipamorelin in off-time starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Weekly Timing

The most-asked scheduling question for Ipamorelin in weekly timing is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Maintenance Phase

For maintenance phase scheduling, Ipamorelin is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	200-300 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	120-300 mcg	4–6 weeks initial cycle
Protocol focus	SubQ	200-300 mcg	1-3x daily SubQ
Maintenance phase	SubQ	140-300 mcg	Ongoing with periodic pauses

Dose timing for Ipamorelin is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

Ipamorelin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

Ipamorelin + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Ipamorelin's mechanism in protocol / scheduling / cycling protocols.
Ipamorelin + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Ipamorelin's mechanism in protocol / scheduling / cycling protocols.
Ipamorelin + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Ipamorelin's mechanism in protocol / scheduling / cycling protocols.
Ipamorelin + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with Ipamorelin's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Banned (S2) FDA: Unapproved Research: Phase II in GH deficiency; off-label use widespread

Cleanest side-effect profile among GHRPs. Mild flushing possible. Site reactions occasional.

Lens-specific safety considerations for protocol / scheduling / cycling use of Ipamorelin: Cleanest side-effect profile among GHRPs. Mild flushing possible. Site reactions occasional. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Ipamorelin selective growth hormone secretagogue

PMID 9849822

Supporting

Ipamorelin clinical pharmacology

PMID 10882754

Ipamorelin vs Related Peptides

Compound	Profile	Onset	Best For
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Daily timing for Ipamorelin?

Pragmatic timing depends on pharmacokinetics: single daily dose for moderate half-life. Consistent timing matters more than the absolute clock time of any single dose.

Stack timing relative to training and meals?

Fasted dosing for GH-axis and AMPK-engaging compounds; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it. Training-day-only versus daily dosing depends on the compound and the volume of training; verify against the specific protocol.

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

How does Ipamorelin's half-life affect dosing?

Ipamorelin has a plasma half-life of ~2 hr, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 1-3x daily subq dosing at 200-300 mcg per dose explains the typical onset timeline for scheduling and cycle endpoints.

What is the standard dosing protocol for Ipamorelin?

Conventional Ipamorelin dosing is 200-300 mcg 1-3x daily subq via subq. For scheduling and cycle use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

Clinical Protocol

Start a Ipamorelin Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified Ipamorelin and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 712 Da
Sequence length: 5 aa
Half-life: ~2 hr
WADA: Banned (S2)
FDA: Unapproved
Research: Phase II in GH deficiency; off-label use widespread

Stack Partners

BPC-157

TB-500

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Ipamorelin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for Ipamorelin

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised